Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  Forster, Rachel ^a   Stewart, Marlene ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DIRECT ORAL ANTICOAGULANT; HEPARIN; PLACEBO; UNCLASSIFIED DRUG; VITAMIN K GROUP;

CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HIP ARTHROPLASTY; HIP FRACTURE; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLEEDING; CHEMICALLY INDUCED; HIP FRACTURES; HIP REPLACEMENT; KNEE REPLACEMENT;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; HEMORRHAGE; HEPARIN; HIP FRACTURES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84962168148     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004179.pub2     Document Type: Review

References (96)

1. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine 2010;363(26):2487-98.
2. NCT00423319 . Study of an investigational drug for the prevention of thrombosis-related events following hip replacement surgery (ADVANCE-3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&rank=1 (accessed 30 August 2015).
3. Pineo GF, Gallus AS, Raskob GE, Chen D, Ramirez L-M, Ramacciotti E, et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis 2013;11(3):444-51.
4. Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Lassen MR. Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8, 464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116.
5. Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. Journal of Bone and Joint Surgery. British Volume 2012;94(2):257-64.
6. Barrellier MT, Lebel B, Parienti JJ, Mismetti P, Dutheil JJ, Vielpeau C, et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research 2010;126(4):e298-304.
7. Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International 2000;9(45):197-98.
8. Arnesen H, Dahl OE, Aspelin T, Seljeflot I, Kierulf P, Lyberg T. Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis 2003;1(5):971-5.
9. Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, et al. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis 1997;77(1):26-31.
10. Dahl OE, Andreassen G, Muller C, Mathisen P, Nyhus S, Aspelin T, et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis 1995;73(6):1094-Abstract No 743.
11. Lassen MR, Borris LC. Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty - a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104.
12. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Andersen G, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research 1998;89(6):281-7.
13. Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research 2009;123(3):488-94.
14. Hull RD. New insights into extended prophylaxis after orthopaedic surgery - the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95-100.
15. Hull RD, Pineo GF, Francis C, Bergqvist, D, Fellenius C, Soderberg K, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine 2000;160(14):2208-15.
16. Planes A, Vochelle N. The post-hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics 1997;20(2 Suppl):18-21.
17. Planes A, Vochelle N, Compan D, Weisslinger N, Huet Y. Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274.
18. Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Compan D, et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. Drugs 1996;52(Suppl 7):47-54.
19. Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348(9022):224-8.
20. Planes A, Vochelle N, Darmon JY. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the French study--venographic outcome at 35 days. Chest 1998;114(2 Suppl Evidence):125S-9S.
21. Heit JA, Elliott CG, Trowbridge AA, Hirsh J, Gent M. Extended out-of-hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood 1998;92:500a.
22. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 2000;132(11):853-61.
23. Kolb G, Bodamer I, Galster H, Grambach K, Koudela K, Eisele RR, et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868.
24. Kolb G, Bodamer I, Galster H, Seidlmayer C, Grambach K, Koudela K, et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis 2003;90(6):1100-5.
25. Prandoni P, Bruchi O, Sabbion P, Tanduo C, Scudeller A, Sardella C, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine 2002;162(17):1966-71.
26. Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/ 2008.
27. Cohn DM, Hermanides J, Devries JH, Kamphuisen PW, Kuhls S, Homering M, et al. Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis 2012;107(2):225-231.
28. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts) 2007;110(11):6.
29. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology 2008;141(Suppl 1):82.
30. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine 2008;358(26):2765-75.
31. Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume 2009;91(5):636-44.
32. Eriksson BI, Rosencher N, Friedman RJ, Homering M, Dahl OE. Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research 2012;130:147-51.
33. Haas S, Borris LC, Friedman RJ, Huisman MV, Kakkar AK, Geerts W, et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis 2008;36(Suppl 1):A15.
34. Lassen MR, Gent M, Kakkar AK, Eriksson BI, Homering M, Berkowitz SD, et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume 2012;94(11):1573-8.
35. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&rank=1 (accessed 30 August 2015).
36. Rosencher N, Llau JV, Mueck W, Loewe A, Berkowitz SD, Homering M. Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica 2013;57(5):565-72.
37. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Bandel TJ, et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short-term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis 2008;36(Suppl 1):A15.
38. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372(9632):31-9.
39. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended thromboprophylaxis with rivaroxaban compared with short-term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts) 2007;110(11):307.
40. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short-term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology 2008;141(Suppl 1):65.
41. Mouret P, Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Muntz J, et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short-term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik 2008;103(3):15.
42. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double-blind, randomized study of BAY 59-7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&rank=1 (accessed 30 August 2015).
43. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): A randomised, double-blind, non-inferiority trial. Thrombosis and Haemostasis 2011;105(4):721-9.
44. Huo M, Eriksson B, Dahl O, Kurth A, Hantel S, Hermasson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial [Abstract No. 0564]. Haematologica 2010; Vol. 92:233.
45. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE-NOVATE&rank=1 (accessed 30 August 2015).
46. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, Van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370(9591):949-56.
47. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, Van Dijk N, Frostick SP, et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW-049). Journal of Thrombosis and Haemostasis 2007;5(Suppl 2):OW-049.
48. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE-NOVATE&rank=2 (accessed 30 August 2015).
49. Samama CM, Vray M, Barre J, Fiessinger JN, Rosencher N, Lecompte T, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Archives of Internal Medicine 2002;162(19):2191-6.
50. Zhang H, Lin J, Li H, Guan Z, Zhou D, Kon B, et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China 2014;94(7):525-8.
51. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. Journal of Bone & Joint Surgery - American Volume 2001;83-A(3):336-45.
52. Spiro TE. A double-blind multicenter clinical trial comparing long term enoxaparin and placebo treatments in the prevention of venous thromboembolic disease after hip and knee replacement surgery. Blood. 1997; Vol. 90, issue Suppl 1:295a.
53. NCT01720108 . Extended venous thromboembolism prophylaxis comparing rivaroxaban to aspirin following total hip and knee arthroplasty (EPCAT II). https://clinicaltrials.gov/ct2/show/NCT01720108 (accessed 30 August 2015).
54. Kristensen SS, Pedersen P, Pedersen NW, Schmidt SA, Kjaersgaard-Andersen P. Combined treatment with indomethacin and low-dose heparin after total hip replacement. Journal of Bone and Joint Surgery. American Volume 1990;72:447-9.
55. Manganelli D, Pazzagli M, Mazzantini D, Punzi G, Manca M, Vignali C, et al. Prolonged prophylaxis with unfractioned heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. Respiration 1998;65(5):369-74.
56. Palla A, Manganelli D, Rossi G. Prolonged prophylaxis with unfractioned heparin (UH) is effective to reduce delayed deep vein thrombosis (DVT) in total hip replacement (THR). European Respiratory Journal. 1997; Vol. 10, issue Suppl 25:5S.
57. Haentjens P, Delince P, The Belgian Nadroparin Post-Hospital Discharge In Orthopedics (NPHDO) Study Group. Prevention of venous thromboembolism after hospital discharge. Continued pharmacologic prophylaxis versus no prophylaxis in patients undergoing total hip replacement. Hip International 2001;11(1):25-36.
58. Haentjens P, The Belgian Nadroparin Post-Hospital Discharge in Orthopedics (NPHDO) Study Group. Post-hospital discharge prevention of deep vein thrombosis with nadroparin calcium after elective total hip replacement. British Journal of Anaesthesia 1999;82(Suppl 1):78.
59. The Belgian Nadroparin Post Hospital Discharge in Orthopedics (NPHDO) Study Group. Post hospital discharge prevention of deep vein thrombosis with nadroparin calcium after total hip arthroplasty. Haemostasis. 1998; Vol. 28, issue Suppl 2:292.
60. Anon . A multicenter, multinational, randomized, double-blind study of fondaparinux sodium (Org31540/SR90107A) versus placebo for the prolonged prevention of VTE in hip fracture surgery. (PENTIHFRA PLUS). Study No: EFC4582. GlaxoSmithKline Clinical Trial Register 2005.
61. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. No episode of thrombocytopenia after four-week administration of fondaparinux, a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study. Journal of Thrombosis and Haemostasis 2003;1(Suppl 1):P2050.
62. Dobesh PP. Novel concepts: emerging data and the role of extended prophylaxis following hip fracture surgery. American Journal of Health-System Pharmacy 2003;60(22 Suppl 7):S15-9.
63. Eriksson BI. A multicenter, randomized, placebo-controlled, double-blind study of fondaparinux for the prolonged prevention of venous thromboembolism in hip fracture surgery. Abstracts of the Sicot/Sirot XXII World Congress 2002:318.
64. Eriksson BI, Lassen MR. Consistency of efficacy of extended thromboprophylaxis with fondaparinux (arixtra) in prevention of venous thromboembolism (VTE) after hip fracture surgery according to different composite efficacy endpoints: the PENTHIFRA-PLUS study. Journal of Thrombosis and Haemostasis 2003;1(Suppl 1):Abstract P2064.
65. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: A multicenter, randomized, placebo-controlled, double-blind study. Archives of Internal Medicine 2003 Jun 9;163(11):1337-42.
66. Eriksson BI, Lassen MR, Colwell CW, Jr . Efficacy of fondaparinux for thromboprophylaxis in hip fracture patients. Journal of Arthroplasty 2004;19(7 Suppl 2):78-81.
67. Lassen M, Bauer KA, Eriksson BI, Turpie AGG. Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra®) a new synthetic and selective inhibitor of factor Xa in the PENTHIFRA-PLUS study. Journal of Thrombosis and Haemostasis 2003;1(Suppl 1):Abstract number: P2052.
68. Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. New England Journal of Medicine 1996;335(10):696-700.
69. Bergqvist D, Jönsson B. Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement. Haemostasis 2000;30 Suppl 2:130-5.
70. Nilsson PE, Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlund U, et al. The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin. Orthopedics 1997;20 Suppl:22-5.
71. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-4.
72. Cushman M. Epidemiology and risk factors for venous thrombosis. Seminars in Hematology 2007;44(2):62-9.
73. Dotzel, MM . Determination that ardeparin sodium injection was not withdrawn from sale for reasons of safety or effectiveness. US Food and Drug Administration 2002:http://www.fda.gov/ohrms/dockets/98fr/052302b.htm (date accessed September 2015).
74. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
75. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001;358(9275):9-15.
76. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement [see comments]. New England Journal of Medicine 1997;337(19):1329-35.
77. McMaster University (developed by Evidence Prime, Inc). Available from www.gradepro.org. GRADEpro Guideline Development Tool (GRADEpro GDT). McMaster University (developed by Evidence Prime, Inc). Available from www.gradepro.org, 2015.
78. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):7S-47S. [DOI: 10.1378/chest.1412S3]
79. Heit JA. Epidemiology of venous thromboembolism. Nature Reviews Cardiology 2015;12:464-74. [DOI: 10.1038/nrcardio.2015.83]
80. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
81. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
82. Hirsh J. Evidence for the needs of out-of-hospital thrombosis prophylaxis: introduction. Chest 1998;114(2 Suppl Evidence):113S-4S.
83. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet 1998;351(9096):123-7.
84. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1, 984 patients. Chest 1998;114(2 Suppl II):115S-8S.
85. Liew A. Extended-duration new oral anticoagulants for venous thromboprophylaxis in patients undergoing total hip arthroplasty: A meta-analysis of the randomized controlled trials. Journal of Thrombosis and Haemostasis 2014;12(1):107-9.
86. Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM. Prophylactic agents for venous thrombosis in elective hip surgery: Meta-analysis of studies using venographic assessment. Archives of Internal Medicine 1993;153(19):2221-8.
87. National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Methods evidence and guidance. http://www.nice.org.uk/guidance/cg92/evidence/cg92-venous-thromboembolism-reducing-the-risk-full-guideline3 (accessed September 2015).
88. National Clinical Guideline Centre. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical Guideline. Methods, evidence and recommendations. http://www.nice.org.uk/guidance/cg144/evidence/cg144-venous-thromboembolic-diseases-full-guideline3 (accessed September 2015).
89. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340(8812):152-6.
90. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
91. Robinson KS, Anderson DR, Gross M, Petrie D, Leighton R, Stanish W, et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Annals of Internal Medicine 1997;127(6):439-45.
92. Scottish Intercollegiate Guidelines Network. Thrombosis Guidelines Prevention and management of venous thromboembolism. A national clinical guideline. http://www.sign.ac.uk/pdf/sign122.pdf (accessed September 2015).
93. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ (Clinical research ed.) 1994;309(6965):1351-5.
94. Wang Z, Anderson FA Jr, Ward M, Bhattacharyya T. Surgical site infections and other postoperative complications following prophylactic anticoagulation in total joint arthroplasty. PLoS ONE 2014;9(4):e91755. [10.1371/journal.pone.0091755. eCollection 2014]
95. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I-4-I-8.
96. Quinlan DJ, Eikelboom JW, Douketis JD. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD004179]